Modality
Radioligand
MOA
RAS(ON)i
Target
KRASG12C
Pathway
Innate Imm
NBMSWet AMD
Development Pipeline
Preclinical
~Sep 2023
→ ~Dec 2024
Phase 1
Mar 2025
→ Sep 2029
Phase 1Current
NCT08761665
277 pts·MS
2025-03→2029-09·Not yet recruiting
277 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-273.5y awayInterim· MS
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2029-09-27 · 3.5y away
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08761665 | Phase 1 | MS | Not yet recr... | 277 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |